Alexander Goemans
CFO
Xeltis
Antwerp, Belgium
12 profile visitsSpeaker
My organisation
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. Xeltis seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place. Xeltis’ most advanced product currently under clinical development is aXessTM, an implantable blood vessel for hemodialysis vascular access. Xeltis’ groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases.
Xeltis is based in The Netherlands and the USA. Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, Ysios Capital, Grand Pharma Group, the European Innovation Council and Invest-NL, in addition to other public and private investors.
Speaker sessions (1)
Tuesday, 23 September 2025
13:30 - 14:50
2. Interactive Panel - funding health innovation: Two startups journeys, two investor perspectives
Location:Pop artTrack:Track 4 - Finance
- Public-private funding
- Financing innovation
Two startups share their funding journeys, from grants to private capital; joined by top EU investors on what drives decisions today. A clear look at how to finance innovation in biotech, medtech, and digital health, and how founders can stand out.